XML 84 R68.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration, License and Other Strategic Agreements (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 03, 2017
Feb. 28, 2017
Jul. 31, 2015
Mar. 31, 2018
Sep. 30, 2017
Jun. 30, 2017
Dec. 31, 2015
Dec. 31, 2017
Collaborative Agreements                
Asset acquisition, contingent consideration liability       $ 20,000       $ 0
Endoceutics, Inc.                
Collaborative Agreements                
Payments related to collaborative arrangement $ 50,000              
Number of shares issued under arrangement 600,000              
Net shares issued in connection with license agreement, value $ 13,500              
Consideration recorded           $ 83,500    
IPR&D expense           5,800    
Endoceutics, Inc. | 180 Day Lock-Up Provision                
Collaborative Agreements                
Number of shares issued under arrangement 300,000              
Stock issued, lock-up period 180 days              
Endoceutics, Inc. | One Year Lock-Up Provision                
Collaborative Agreements                
Number of shares issued under arrangement 300,000              
Stock issued, lock-up period 1 year              
Palatin Technologies, Inc.                
Collaborative Agreements                
Payments related to collaborative arrangement   $ 60,000            
Out-of-pocket expenses (up to)   $ 25,000            
Velo Bio, LLC                
Collaborative Agreements                
Upfront payment, option agreement             $ 10,000  
Velo Bio, LLC | Option Exercise and Regulatory Milestone Achievement                
Collaborative Agreements                
Future contingent payments (up to)     $ 65,000          
Velo Bio, LLC | Annual Sales Milestone Achievements                
Collaborative Agreements                
Future contingent payments (up to)     250,000          
Velo Bio, LLC | Annual Sales Milestone Achievements | Minimum                
Collaborative Agreements                
Sales milestone targets     100,000          
Velo Bio, LLC | Annual Sales Milestone Achievements | Maximum                
Collaborative Agreements                
Sales milestone targets     $ 900,000          
Velo Bio, LLC | Royalty Threshold Achievement                
Collaborative Agreements                
Potential milestone payment, triggering event, royalty percentage     0.00%          
Potential milestone payment, increased percentage     50.00%          
Intrarosa | Endoceutics, Inc.                
Collaborative Agreements                
Out-of-pocket expenses (up to)         $ 20,000      
Intrarosa | Endoceutics, Inc. | Developed technology rights                
Collaborative Agreements                
Finite-lived intangible assets           $ 77,700    
Intrarosa | Endoceutics, Inc. | Delivery Of Intrarosa Launch Quantities                
Collaborative Agreements                
Payments related to collaborative arrangement         $ 10,000      
Asset acquisition, contingent consideration liability       10,000        
Intrarosa | Endoceutics, Inc. | First Anniversary Of Closing                
Collaborative Agreements                
Asset acquisition, contingent consideration liability       10,000        
Intrarosa | Endoceutics, Inc. | Tiered Royalties                
Collaborative Agreements                
Potential milestone payment, triggering event, sales $ 150,000     $ 150,000        
Royalty percentage, maximum 20.00%     20.00%        
Net sales threshold, future contingent payments $ 1,000,000     $ 1,000,000        
Period after first commercial sale 10 years     10 years        
Intrarosa | Endoceutics, Inc. | First Sales Milestone Achievement                
Collaborative Agreements                
Asset acquisition, contingent consideration liability $ 15,000     $ 15,000        
Potential milestone payment, triggering event, sales 150,000     150,000        
Intrarosa | Endoceutics, Inc. | Second Sales Milestone Achievement                
Collaborative Agreements                
Asset acquisition, contingent consideration liability 30,000     30,000        
Potential milestone payment, triggering event, sales 300,000     300,000        
Intrarosa | Endoceutics, Inc. | Third Sales Milestone Achievement                
Collaborative Agreements                
Asset acquisition, contingent consideration liability 850,000     850,000        
Potential milestone payment, triggering event, sales $ 500,000     $ 500,000        
Bremelanotide Products | Palatin Technologies, Inc. | Tiered Royalties                
Collaborative Agreements                
Period after first commercial sale       10 years        
Bremelanotide Products | Palatin Technologies, Inc. | First Sales Milestone Achievement                
Collaborative Agreements                
Asset acquisition, contingent consideration liability       $ 25,000        
Potential milestone payment, triggering event, sales       250,000        
Bremelanotide Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement                
Collaborative Agreements                
Asset acquisition, contingent consideration liability       80,000        
Bremelanotide Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application                
Collaborative Agreements                
Asset acquisition, contingent consideration liability       20,000        
Bremelanotide Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval                
Collaborative Agreements                
Asset acquisition, contingent consideration liability       60,000        
Bremelanotide Products | Palatin Technologies, Inc. | Achievement of Certain Annual Sales Milestones over Course of License Agreement                
Collaborative Agreements                
Asset acquisition, contingent consideration liability       $ 300,000